Oncology

Cancer/Oncology Market Research Reports & Consulting

Find Cancer/Oncology market research reports and Cancer/Oncology industry analysis including industry overviews, market segmentation data, market share and growth.

Market Reports

Title	Published	Price
Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020) Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.	December 2011	$ 4650
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020) Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.	December 2011	$ 4650
Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020) The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.	December 2011	$ 4650
Leukemia Therapeutics Market (2010-2020) (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid Leukemia) Pipeline Forecast & Market Forecast in G8 Countries Leukemia is the type of blood cancer and the ninth most common one in males. It accounts for almost 0.0148% of all the men and 0.009% of all the women worldwide. The leukemia market is segmented into four types; namely acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. The market was dominated by chronic myeloid leukemia in 2010. However, in 2020, the market is expected to be equally dominated by acute lymphocytic leukemia and chronic myeloid leukemia.	November 2011	$ 6500
Prostate Cancer Therapeutics Market (2010-2020) (Opportunity Analysis, Pipeline Assessment and Global Market Forecast) Prostate cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer-related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost.	November 2011	$ 4650
Lung Cancer Therapeutics Market (NSCLC & SCLC) - 2010-2020 (Pipeline Assessment and Market Forecast) in G7 countries Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.	November 2011	$ 4650
Global Lung Cancer Surgery Market (Devices & Treatment Outlook) – Trends & Challenges (2010 – 2015) The lung cancer surgery market is expected to grow at a CAGR of 4.9% during the study period (2010-2015). Thoracotomy is the most widely used surgical procedure for lung cancer treatment accounting for about 74% of all surgical interventions.	June 2011	$ 4650
Global Cancer Biomarkers Market (2010 - 2015) Cancer is recognized as a major cause of mortality world over; accounting for 7.4 million (or 13%) of all deaths in 2004. The WHO estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015. The rising prevalence of the disease forms one of the major factors driving the growth of the oncology biomarkers market.	June 2010	$ 4650
Global Multiple Myeloma Drugs Market 2008 saw almost 12 million patients diagnosed with cancer. Despite, increasing technological advancements and research the deaths due to cancer were about 8 million people in 2008. Lung cancer accounts for the highest mortality rate. There has been a significant development in technologies and drugs/vaccines with respect to breast cancer, thyroid cancer, and pancreatic cancer therefore increasing the survival rates.	March 2012	$ 4650
Global Breast Cancer Drugs Market There are about one million new cases of breast cancer every year. Breast cancer accounts for about 10% of world wide cancer. There has been significant increase in awareness levels with respect to impact on survival rates incase of early diagnosis. Therefore, opening novel opportunities for breast cancer drugs market.	March 2012	$ 4650
Global Colorectal Cancer Market (2010-2015) 2008 saw almost 12 million patients diagnosed with cancer. Despite, increasing technological advancements and research the deaths due to cancer were about 8 million people in 2008. Lung cancer accounts for the highest mortality rate.	March 2012	$ 4650
Global Oncology Pharmaceuticals & Therapeutics Market Each section of the report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints and opportunities. The report contains strategic section with respect to competitive landscape and market overview. The report will encompass more than 40 company profiles.	March 2012	$ 4650